Allergan Inc.  (AGN) Trade Now »     Rate AGN  -  Discuss AGN  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

AGN Analysis & Videos »


AGN: Bull or Bear?

FDA Calendar: Allergan's New Rx for Eyelashes AGN

73%

+24.49% in 187 days FDA Calendar: Allergan's New Rx for Eyelashes <> The accompanying table [click to enlarge] includes an updated FDA calendar of 65 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with six companies listed in red with overdue decisions and the possibility for five decisions during the coming week. Click here for my previous FDA calendar articles and below is a review of recent decisions + a preview of the coming week: 1.) Allergan (AGN) received FDA approval on Friday for Latisse (bimatoprost solution 0.0... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/28/08

Comment

Allergan Wants To Improve Your Eyelashes AGN

73%

-6.59% in 22 days (closed on 12/28/08) FDA Calendar: A Weekly Update <> <> The accompanying table [click to enlarge] presents an updated calendar of 74 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week. 1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standard< />< />< />< /><>< />< />< />< />< />< />< />< /><>< />< />< />< /><>< />< /><>< />< /><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/06/08

Comment

Cosmetic & Reconstructive Medicine: An Industry Profile AGN

73%

-1.57% in 55 days (closed on 12/06/08) Cosmetic & Reconstructive Medicine : An Industry Profile <> Cosmetic & Reconstructive Medicine Index <> Top 5 Companies by Market Cap Top 5 Companies by 52-Week Stock Price Change <> <> The accompanying tables present an overview of my 48-company Global Cosmetic and Reconstructive Medicine (CRM) Index which includes companies engaged in skin care, cosmetic medicine, regenerative medicine, orthopedic repair, and joint replacements. The performance over the past year of my CRM Index compares favorably to benchmark ETFs such as HealthShares C... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  10/12/08

Comment

Allergan Inc. AGN

62%

-9.69% in 361 days Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for glaucoma therapy, ocular inflammation, infection, allergy, and chron... Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  07/07/08

Comment

Allergan Premium Makes It a Hold AGN

-11.24% in 374 days We believe these acquisitions will provide Allergan with the opportunity to drive growth in its existing business and to expand into new areas of business. Continue reading »

By  Zacks.com   (-19.65%  risk: moderate)  06/24/08

Comment

Cramer on BloggingStocks: Europe is starting to eye U.S. gems AGN

-12.69% in 421 days Filed under: Deals, Market matters, Allergan (AGN), Citigroup Inc. (C), Sprint Nextel Corp (S), Unilever ADR (UL), Stocks to Buy, Cramer on BloggingStocks TheStreet.com's Jim Cramer says the exchange rate plus massive undervaluations make the great brands prime targets. There's always been a groupthink in Europe about currencies. The companies that want to buy American companies have, at times, seemed to care more about the currency, or at least not buying a company in a country whose currency is in decline, than they care about the actual target. That's what it looks like now that a lar... Continue reading »

By  Jim Cramer   (-8.74%  risk: moderate)  05/08/08

Comment

People Bullish on AGN

william0509 Associate 67% 2 mos ago	Mike Havrilla Principal 73% 6 mos ago	pafoxhunter Analyst 78% 6 mos ago
Statistician Analyst N/A 7 mos ago	Art Analyst N/A 7 mos ago

People Bearish on AGN

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.